Global Sepsis Diagnostics Market - Segmented by Technology, Product, Diagnostic Method, Pathogen and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4557822
  • Report
  • Region: Global
  • 110 pages
  • Mordor Intelligence
1 of 4

FEATURED COMPANIES

  • Abbott
  • BioMérieux SA
  • Bruker
  • F. Hoffmann-LA Roche Ltd
  • Luminex Corporation
  • Qiagen
  • MORE
The sepsis diagnostics market is expected to register a growth rate of nearly 8.0% during the forecast period, 2018-2023. Rising prevalence of sepsis and hospital acquired infections has led to increased awareness among public especially in industrialized countries for its early diagnosis which primarily drives its market. The well-established healthcare infrastructure with high adoption of advanced diagnostic technologies and rising awareness for early disease diagnosis, are expected to help dominate the market share of North America in the forecast period.

Growing Incidence of Hospital Acquired Infections

The increased incidence of hospital acquired infections (HAIs) is one of the primary factor leading to growth of the sepsis diagnostics market. The HAIs can trigger sepsis particularly in people who are already at risk such as those with chronic diseases like diabetes or who are immunocomprimised such as under chemotherapy or don’t have a spleen including very young population or very old population. According to Center for Disease Control and Prevention, on any given day in a hospital in the US, about one among 25 hospital patients has atleast one healthcare associated infection. Thus, with the rising number of HAIs, there is rising demand for sepsis diagnostics driving this market.

Other driving factors for this market include increasing prevalence of sepsis, growing number of pneumonia cases and rise in the number of sepsis procedure alongwith increase in the funding for sepsis-related research activities.

Lack of Well Established Reimbursement Policies for Sepsis

There are several changes in the reimbursement policies related to sepsis particularly related with hospitals which restricts the growth of the sepsis diagnostics market. Several hospitals are reducing the reimbursement amount for sepsis which is majorly related to mishandling and lack of good documentation for sepsis to get past the approval from the insurers. Several hospitals hide the details of patients such as discharged status from hospitals to the universal health insurance policies which impacts the reimbursement for sepsis. Thus, it is one of the major factor hindering the growth of this market

Other factors limiting the growth of this market are high cost of automated diagnostic instruments, low awareness regarding sepsis and shortage of skilled professionals particularly in the emerging markets.

Asia Pacific to Witness the Fastest Growth Rate

Asia Pacific is expected to dominate the fastest growth rate in the forecast period. The healthy CAGR is expected due to rising healthcare expenditure in countries such as India, China and Japan. This is accompanied by increasing government initiatives for cancer awareness, rise in research and development investments. Further, it is followed by the wide diversified patient pool of infectious diseases and other chronic diseases. North America is expected to dominate the market share well-established healthcare infrastructure, aging population with the better regulatory framework and government support in the countries of this region.

Key Developments in the Market
  • April, 2018 - Curetis NV announced that its collaborated partner Acumen Research Laboratories Pte. Ltd received approval for Unyvero BCU Cartridge for bloodstream infections in Singapore.
Major Players: ABBOTT, AXIS-SHIELD DIAGNOSTICS LTD, BECTON DICKINSON AND COMPANY, BIOMÉRIEUX SA, BRUKER, QIAGEN, F. HOFFMANN-LA ROCHE LTD, LUMINEX CORPORATION, T2 BIOSYSTEMS INC, AND THERMO FISHER SCIENTIFIC, amongst others.

Reasons to Purchase this Report
  • Current and future of sepsis diagnostics market outlook in the developed and emerging markets
  • Analysis of various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 months analyst support, along with the Market Estimate sheet (in excel)
Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your need.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott
  • BioMérieux SA
  • Bruker
  • F. Hoffmann-LA Roche Ltd
  • Luminex Corporation
  • Qiagen
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Market Dynamics
6.1 Market Drivers
6.1.1 Increasing Prevalence of Sepsis
6.1.2 Growing Incidence of Hospital Acquired Infections
6.1.3 Growing Number of Pneumonia Cases
6.1.4 Rise in the Number of Sepsis Procedures and Increase in Funding for Sepsis-Related Research Activities
6.2 Market Restraints
6.2.1 High Cost of Automated Diagnostic Instruments
6.2.2 Lack of Well Established Reimbursement Policies for Sepsis
6.2.3 Low Awareness Regarding Sepsis and Shortage of Skilled Professionals in Emerging Markets
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Technology
7.1.1 Molecular Diagnostics
7.1.1.1 Polymerase Chain Reaction
7.1.1.2 Fluorescent in Situ Hybridization
7.1.1.3 Microarrays
7.1.1.4 Others
7.1.2 Biomarkers
7.1.3 Immunoassays
7.1.4 Flow Cytometry
7.1.5 Others
7.2 By Product
7.2.1 Blood Culture Media
7.2.2 Instruments
7.2.3 Assays & Reagents
7.2.4 Software
7.3 By Diagnostic Method
7.3.1 Coventional Diagnostics
7.3.2 Automated Diagnostics
7.4 By Pathogen
7.4.1 Bacterial Sepsis
7.4.1.1 Gram-Positive Bacterial Sepsis
7.4.1.2 Gram-Negative Bacterial Sepsis
7.4.2 Fungal Sepsis
7.4.3 Others
7.5 By Geography
7.5.1 North America
7.5.1.1 US
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 Germany
7.5.2.3 UK
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest of Europe
7.5.3 Asia-Pacific
7.5.3.1 China
7.5.3.2 Japan
7.5.3.3 India
7.5.3.4 Australia
7.5.3.5 South Korea
7.5.3.6 Rest of Asia-Pacific
7.5.4 Middle East & Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of MEA
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 Abbott
9.2 Axis-Shield Diagnostics Ltd
9.3 Becton Dickinson and Company
9.4 BioMérieux SA
9.5 Bruker
9.6 Qiagen
9.7 F. Hoffmann-LA Roche Ltd
9.8 Luminex Corporation
9.9 T2 Biosystems Inc
9.10 Thermo Fisher Scientific
*List Not Exhaustive

10. Future Market Outlook
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott
  • Axis-Shield Diagnostics Ltd
  • Becton Dickinson and Company
  • BioMérieux SA
  • Bruker
  • Qiagen
  • F. Hoffmann-LA Roche Ltd
  • Luminex Corporation
  • T2 Biosystems Inc
  • Thermo Fisher Scientific
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll